Italia markets closed

Kyowa Kirin Co., Ltd. (KYKOF)

Other OTC - Other OTC Prezzo differito. Valuta in USD.
Aggiungi a watchlist
16,350,00 (0,00%)
Alla chiusura: 03:40PM EST
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente16,35
Aperto16,25
Denaro0,00 x 0
Lettera0,00 x 0
Min-Max giorno16,35 - 16,35
Intervallo di 52 settimane16,06 - 22,85
Volume3.561
Media Volume741
Capitalizzazione8,851B
Beta (5 anni mensile)0,21
Rapporto PE (ttm)22,40
EPS (ttm)0,73
Prossima data utiliN/D
Rendimento e dividendo (futuro)0,41 (2,50%)
Data ex dividendo28 dic 2023
Stima target 1AN/D
  • GlobeNewswire

    Kyowa Kirin to Acquire Orchard Therapeutics

    -Orchard Therapeutics is a global gene therapy leader with experience successfully developing and commercializing medicines for rare diseases--Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps resource the ongoing and future launches of Libmeldy® (atidarsagene autotemcel)--Acquisition price of $16.00 per ADS in cash plus an additional contingent value right of $1.00 per ADS, representing a t

  • GlobeNewswire

    Tenapanor for Hyperphosphatemia Approved in Japan

    Approval announced by Kyowa Kirin, Ardelyx Collaboration Partner Ardelyx to receive $30 million from Kyowa Kirin in milestone and license amendment payments and $5 million from HealthCare Royalty Partners under a Financing Agreement WALTHAM, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced